Man dies after being left brain-dead in French drug trial

Image
AFP Rennes (France)
Last Updated : Jan 17 2016 | 9:32 PM IST
A man who was left brain-dead after suffering serious side-effects during a drugs trial in France died today, according to the hospital which had been treating him.
Five other volunteers hospitalised a week ago when the drugs trial went wrong were "in a stable condition", the hospital in the western city of Rennes said in a statement.
The private laboratory Biotrial was testing a new pain and mood disorder medication for Portuguese pharmaceutical company Bial on humans for the first time, in what is known as a Phase I trial, to test the drug's safety.
A total of 108 volunteers took part in the trial, 90 of whom received the drug while the rest were given placebos.
The six men who were hospitalised were the group which received the highest dose.
Pierre-Gilles Edan, head of the neurology department at the Rennes hospital said Friday that three of the men were suffering a "handicap that could be irreversible" and another also had neurological problems.
The sixth volunteer had no symptoms but was being monitored.
"The 84 other volunteers exposed to the drug" have been contacted, said the hospital. Ten of them came in to be examined and did not have the "anomalies" seen in the hospitalised patients.
The incident is the worst of its kind ever to have taken place in France, and such mishaps are rare during drug trials.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 17 2016 | 9:32 PM IST

Next Story